Skip to main content
SpringerLink
Log in

Kombinierte Therapien

  • Chapter
Book cover Neuro-Psychopharmaka Ein Therapie-Handbuch

  • 87 Accesses

Zusammenfassung

Die Therapie des Parkinson-Syndroms stellt — sieht man von einer beginnenden, die Aktivitäten des Kranken nicht wesentlich behindernden Symptomatik ab — frÜher oder später eine Kombinationsbehandlung mit einem oder mehreren Parkinsonmitteln dar. Es hat sich gezeigt, daß alle in den vorangegangenen Kapiteln besprochenen Substanzgruppen miteinander kombiniert werden kÖnnen. Es herrscht des weiteren übereinstimmung darüber, daß die L-Dopa-Substitutionstherapie die Basisbehandlung des Parkinson-Syndroms darstellt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Appleton DB, Eadie MJ, Sutherland JM (1970) Amantadine hydrochloride in the treatment of parkinsonism: a controlled trial. Med J Aust 2: 626–629

    PubMed  CAS  Google Scholar 

  • Barbeau A, Mars H, Botez MI, Joubert M (1971) Amantadine — HCl (Symmetrel) in the management of Parkinson’s disease. Double-blind crossover study. Can Med Assoc 105: 42–46

    CAS  Google Scholar 

  • Beasly BL, Nutt JG, Davenport RW, Chase TN (1980) Treatment with tryptophan of levodopa-associated psychiatric disturbances. Arch Neurol 37: 155–156

    Article  Google Scholar 

  • Benkert O, Hippius H (1996) Psychiatrische Pharmakotherapie. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Berger JR, Weiner WJ (1985) Exacerbation of Parkinson’s disease following the withdrawal of amantadine. Neurology 35[Suppl 1]: 200

    Google Scholar 

  • Bianchine JR, Sunyapridakul L (1973) Interactions between levodopa and other drugs: significance in the treatment of Parkinson’s disease. Drugs 6: 364–388

    Article  PubMed  CAS  Google Scholar 

  • Birkmayer W, Riederer P (1985) Die Parkinsonkrankheit. Biochemie, Klinik, Therapie, 2. Aufl. Springer, Wien New York, S 36–48

    Google Scholar 

  • Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-Deprenyl to Madopar® treatment in Parkinson’s disease: a long-term study. J Neural Transm 64: 113–127

    Article  PubMed  CAS  Google Scholar 

  • Bonucelli U, D’Antonio P, D’Avino C, Piccini P, Muratorio A (1995) Dihydroergocryptine in the treatment of Parkinson’s disease. J Neural Transm 45 [Suppl]: 239–245

    Google Scholar 

  • Calne D, Horowski R, Mc Donald RJ, Wuttke W (eds) (1981) Lisuride and other dopamine agonists. Raven Press, New York

    Google Scholar 

  • Csanda E, Tarczy M (1983) Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand [Suppl] 95: 117–122

    Article  CAS  Google Scholar 

  • Csanda E, Tarczy M (1987) Selegiline in the early and late phases of Parkinson’s disease. J Neural Transm [Suppl] 25: 105–113

    CAS  Google Scholar 

  • Dallos V, Heatherfield K, Stone P, Alten FAD (1970) Use of amantadme in Parkinson’s disease. Results of a double blind trial. Br Med J 4: 24–36

    Article  PubMed  CAS  Google Scholar 

  • de Devlttis E, D’Andrea F, Signorelli CD, Cerillo A (1972) L’amantadine nel trattamento dell’ ipokinesia transitoria di pazienti parkinsoniani in corso di terapia con L-Dopa. Minerva Med 409: 4007–4008

    Google Scholar 

  • Deuschl G (1992) Tremor. In: Hopf HC, Poeck K, Schliack H (Hrsg) Neurologie in Praxis und Klinik. Thieme, Stuttgart New York, S 4.53–4.61

    Google Scholar 

  • Duvoisin RC, Barret C, Schear M, Hoehn M, Yahr MD (1969) The use of L-Dopa in parkinsonism. In: Gillingham GFJ, Donaldson JML (eds) The Third Symposium on Parkinson’s Disease. Livingstone, Edinburgh, pp 185–192

    Google Scholar 

  • Factor SA, Weiner WJ (1993) Early combination therapy with bromocriptine and levodopa in Parkinson’s disease. Mov Disord 8: 257–262

    Article  PubMed  CAS  Google Scholar 

  • Fahn S, Isgreen WP (1975) Long term evaluation of amantadine and levodopa combination in parkinsonism by double blind cross-over analyses. Neurology 25: 695–700

    Article  PubMed  CAS  Google Scholar 

  • Fahn S, Marsden C D, Calne D, Goldstein M (eds) (1987) Recent developments in Parkinson’s disease. Macmillan Healthcare Information, New Jersey

    Google Scholar 

  • Fehling C (1973) The effect of adding amantadine to optimum L-Dopa dosage in Parkinson’s syndrome. Acta Neurol Scand 49: 245–251

    Article  PubMed  CAS  Google Scholar 

  • Fischer PA (1988) Aktuelle Parkinsontherapie: Heutiges Konzept für die Anwendung von L-Dopa. Akt Neurol 15: 38–41

    Article  Google Scholar 

  • Fischer PA, Baas H (1987) Therapeutic efficacy of R-(-)-deprenyl therapy in advanced parkinsonism. J Neural Transm [Suppl] 25: 137–147

    CAS  Google Scholar 

  • Fischer PA, Frieling B (1989) (Hrsg) Morbus Parkinson — neue MÖglichkeiten mit Lisurid. De Gruyter, Berlin New York

    Google Scholar 

  • Fischer PA, Przuntek H, Maier M, Welzel D (1984) Kombinationsbehandlung frÜher Stadien des Parkinson-Syndroms mit Bromocriptin und Levodopa. Dtsch Med Wochenschr 109:1279–1283

    Article  PubMed  CAS  Google Scholar 

  • Flückiger E, Briner U, Enz A, Markstein R, Vigouret M (1983) Dopaminergic ergot compounds: an overview. In: Calne D et al. (eds) Lisuride and other dopamine agonists. De Gruyter, Berlin New York, pp 59–88

    Google Scholar 

  • Friedman J H, Lannon MC (1989) Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology 39: 1219–1221

    Article  PubMed  CAS  Google Scholar 

  • Frieling B (1989) Klinische PrÜfung der oralen Lisurid-Therapie bei Morbus Parkinson. In: Fischer PA, Frieling B (Hrsg) Morbus Parkinson — neue MÖglichkeiten mit Lisurid. De Gruyter, Berlin New York, S 59–88

    Google Scholar 

  • Fuxe K, Calne D (eds) (1979) Dopaminergic ergot derivates and motor function. Pergamon Press, Oxford New York Toronto Sydney Paris Frankfurt

    Google Scholar 

  • Garcia CA, Tweedy JR, Blass JP, Mc Dowell FH (1982) Lecithin and Parkinson dementia. In: Corkin S et al. (eds) Alzheimer’s disease: a report of progress in research. Raven Press, New York, pp 443–443449 (Aging, vol 19)

    Google Scholar 

  • Gianutsos G, Chute S, Dunn JP (1985) Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 110: 357–361

    Article  PubMed  CAS  Google Scholar 

  • Giménez-Roldan S, Tolosa E, Burguera JA, Chacón J, Liaño H, Forcadell F (1997) Early combination of bromocriptine and levodopa in Parkinson’s disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 20: 67–76

    Article  PubMed  Google Scholar 

  • Godwin-Austen RB, Frears CC, Bergmann S, Parkes JO, Knill-Jones RP (1970) Combined treatment of parkinsonism with L-Dopa and amantadine. Lancet ii: 383–385

    Article  Google Scholar 

  • Gopinathan G, Horowski R, Suchy I (1985) Lisu-ride pharmacology of Parkinson’s disease. Springer, Berlin Heidelberg New York Tokyo, pp 471–514

    Google Scholar 

  • Greulich W, Fenger E, Sackmann A, Gehlen W (1995) Langzeitwirkung der Amantadin-Therapie. In: Fischer PA (Hrsg) Parkinson-Krankheit. Bedeutung nichtdopaminerger FunktionsstÖrungen. Editiones Roche, Basel Grenzach/Wyhlen, S 315–321

    Google Scholar 

  • Hefner R, Fischer PA (1988) Interaktionen von Hochdruck-Therapeutika mit Parkinson-Mitteln. In: Fischer PA (Hrsg) Modifizierende Faktoren bei der Parkinson-Therapie. Editiones Roche, Basel, S 209–219

    Google Scholar 

  • Hefner R, Fischer PA (1989) Zunahme der Parkinson-Symptomatik unter Kalzium-Antagonisten. Nervenarzt 60: 187–188

    PubMed  CAS  Google Scholar 

  • Hefner R, Baas H, Fischer PA (1988) Incompatibility of flunarizine in Parkinson’s disease. In: Bartko D et al. (eds) New trends in clinical neuropharmacology. Libbey, London Paris, pp 314–316

    Google Scholar 

  • Horowski R, Obeso JA (1995) Lisuride. A direct dopamine agonist in the symptomatic treatment of Parkinson’s disease. In: Koller WC, Paulson G (ed) Therapy of Parkinson’s disease. Marcel Dekker, New York Basel Hongkong, pp 219–248

    Google Scholar 

  • Horrocks PM, Vicary DJ, Rees JE, Parkes JD, Marsden CD (1973) Anticholinergic withdrawal and benzhexol treatment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 36: 936–941

    Article  PubMed  CAS  Google Scholar 

  • Hughes RC, Polgar JG, Weightman D, Walton JN (1971) Levodopa in parkinsonism: the effects of withdrawal of anticholinergic drugs. Br Med J 2: 487–941

    Article  PubMed  CAS  Google Scholar 

  • Hunter KR, Stern GM, Laurence DR, Armitage P (1970) Amantadine in parkinsonism. Lancet i: 1127–1129

    Article  Google Scholar 

  • Jorgensen PB, Bergin JD, Haas L, Cunningham JA, Morah DD, Pollock U (1971) Controlled trial of amantadine hydrochloride in Parkinson’s disease. NZ Med J 73: 263–269

    CAS  Google Scholar 

  • Kaufmann H, Elizan T, Yahr MD, Moros D, Van Woert M (1989) Deprenyl monotherapy in patients with early Parkinson’s disease: a clinical and biochemical study. Neurology 39[Suppl 1]: 229 (Abstract)

    Google Scholar 

  • Klawans H L, Goetz C H G, Tanner C M, Glantz R (1985) Studies with bromocriptine, In: Fahn S et al. (eds) Approaches to the use of bromocriptine in Parkinson’s disease. Raven Health Care Communications, New York, pp 37–45

    Google Scholar 

  • Kornhuber J, Bornemann J, Retz W, Hübers M, Riederer P (1989) Memantine displaces [3H] Mk-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589–590

    Article  PubMed  CAS  Google Scholar 

  • Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK 801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206: 297–300

    Article  PubMed  CAS  Google Scholar 

  • Lees AJ, Stern GM (1981) Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 44: 1020–1023

    Article  PubMed  CAS  Google Scholar 

  • Lees AJ on behalf of the Parkinson’s Disease Research Group of the United Kingdom (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson’s disease. BMJ 311: l602–602l607

    Article  Google Scholar 

  • Lieberman AN, Goldstein M (1985) Update on bromocriptine in Parkinson’s disease. In: Calne DB (ed) Drugs for the treatment of Parkinson’s disease. Springer, Berlin Heidelberg New York Tokyo, pp 443–458

    Google Scholar 

  • Lücking CH, Deuschl G, Strahl K, Schenk E (1986) Tremor im FrÜh-und Spätstadium der Parkinson-Krankheit. Editiones Roche, Basel, S 99–113

    Google Scholar 

  • Madersbacher H, Stöhrer M, Richter R, Burgdorfer H, Machen HJ, Mürtz G (1995) Trospium chloride versus oxybutynin: a randomized double blind, multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol 75: 452–456

    Article  PubMed  CAS  Google Scholar 

  • Maier-Hoehn MM, Elton RL (1985) Low dosages of bromocriptine added to levodopa in Parkinson’s disease. Neurology 35: 199–206

    Article  Google Scholar 

  • Markham C H, Diamond SG (1985) Pergolide in the treatment of Parkinson’s disease. In: Calne DB (ed) Drugs for the treatment of Parkinson’s disease. Springer, Berlin Heidelberg New York Tokyo, pp 459–470

    Google Scholar 

  • Martin WK, Loewenson RP, Resch JA, Baker AP (1974) A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson’s disease. Neurology 35: 199–206

    Google Scholar 

  • Olanow CH, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J (1995) The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 38: 771–777

    Article  PubMed  CAS  Google Scholar 

  • Ott BR, Lannon MC (1992) Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol 15: 322–325

    Article  PubMed  CAS  Google Scholar 

  • Parkes JD (1989) Clinical pharmacology of amantadines and derivates. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Springer, Wien New York, pp 335–341

    Chapter  Google Scholar 

  • Poewe W, Gerstenbrand F, Ransmayr G (1987) Experience with selegiline in the treatment of Parkinson’s disease. J Neural Transm [Suppl] 25: 131–135

    CAS  Google Scholar 

  • Przuntek H (1994) Clinical aspects of neuroprotection in Parkinson’s disease. J Neural Transm 43 [Suppl]: 163–169

    CAS  Google Scholar 

  • Przuntek H, Welzel D, Gerlach M, Blümner E, Danielczyk W, Kaiser HJ, Kraus PH, Letzel H, Riederer P, überla K (1996) Early institution of bromocriptine in Parkinson’s disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm 103: 699–715

    Article  PubMed  CAS  Google Scholar 

  • Rabey JM, Oberman Z, Scharf M, Isakov A, Bar M, Graff E (1989) The influence of levodopa on the pharmacokinetics of bromocriptine in Parkinson’s disease. Clin Neuropharmacol 12: 440–447

    Article  PubMed  CAS  Google Scholar 

  • Rabey JM, Schwartz M, Graff E, Harsat A, Vered Y (1990) The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson’s disease. Clin Neuropharmacol 14: 514–522

    Article  Google Scholar 

  • Rascol A, Guirand E, Montrastuc JL, David J, Clanet MJ (1979) Long-term treatment of Parkinson’s disease with bromocriptine. J Neurol Neurosurg Psychiatry 42: 143–150

    Article  PubMed  CAS  Google Scholar 

  • Ring HA, Trimble MR (1991) Affective disturbance in Parkinson’s disease. Int J Geriatr Psychiatry 6: 385–393

    Article  Google Scholar 

  • Rinne UK (1987a) Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a 5-year follow-up. Neurology 37: 826–826

    Article  PubMed  CAS  Google Scholar 

  • Rinne UK (1987b) R-(-)-Deprenyl as an adjuvant to levodopa in the treatment of Parkinson’s disease. J Neural Transm [Suppl] 25: 149–155

    CAS  Google Scholar 

  • Rinne UK (1989) Die Bedeutung einer frÜhzeitigen Kombination von Lisurid und L-Dopa in der Behandlung der Parkinson-Krankheit. In: Fischer PA, Frieling B (Hrsg) Morbus Parkinson — neue MÖglichkeiten mit Lisurid. De Gruyter, Berlin New York, S 99–110

    Google Scholar 

  • Rinne UK (1991) Early use of dopaminerge agonists in the treatment pf Parkinson’s disease. In: Rinne UK, Nagatsu T, Horowski R (eds) International Workshop Parkinson’s Disease, Berlin. Medicom Europe BV, Bussum, pp 326–336

    Google Scholar 

  • Sage JI, Duvoisin RC (1995) Pergolide. In: Koller WC, Paulson G (eds) Therapy of Parkinson’s disease. Marcel Dekker, New York Basel Hongkong, pp 249–259

    Google Scholar 

  • Sandyk R (1985) Parkinsonism induced by Captopril. Clin Neuropharmacol 8: 197–198

    Article  PubMed  CAS  Google Scholar 

  • Schifter R (1985) Neurologie des vegetativen Systems. Springer, Berlin Heidelberg New York Tokyo

    Book  Google Scholar 

  • Schneider E (1995) Alpha-Dihydroergocryptin-Pharmakologie und klinische Effekte. In: Deuschl G (Hrsg) Morbus Parkinson. Alpha-Dihydroergocryptin — ein neuer Dopamin-Agonist. Thieme, Stuttgart New York, S 17–42

    Google Scholar 

  • Schneider E, Bressel M (1988) Behandlung von HarnblasenfunktionsstÖrungen beim Parkinson-Syndrom. In: Fischer PA (Hrsg) Modifizierende Faktoren bei der Parkinson-Therapie. Editiones Roche, Basel, S 221–232

    Google Scholar 

  • Schneider E, Fischer PA, Csiki C (1983) Stellenwert der Anticholinergika in der Behandlung des Parkinson-Syndroms. In: Gänshirt H (Hrsg) Pathophysiologie, Klinik und Therapie des Parkinsonismus. Editiones Roche, Basel, S 257–266

    Google Scholar 

  • Schneider E, Fischer PA, Jacobi P, Grotz A (1984a) Exogene Psychosen beim Parkinson-syndrom. Häufigkeit und Entstehungsbedingungen. Fortschr Neurol Psychiatr 52: 207–214

    Article  PubMed  CAS  Google Scholar 

  • Schneider E, Ziegler B, Jacobi P (1984b) SchlafstÖrungen beim Parkinson-Syndrom. In: Fischer PA (Hrsg) VegetativstÖrungen beim Parkinson-Syndrom. Editiones Roche, Basel, S 163–183

    Google Scholar 

  • Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozopine and fluperlapine. Eur Arch Psychiatr Neurol Sci 235: 60–64

    Article  CAS  Google Scholar 

  • Shannon KM, Goetz CG, Garroll VS, Tanner CM, Klawans HL (1987) Amantadine and motor fluctuations in chronic Parkinson’s disease. Clin Neuropharmacol 6: 522–526

    Article  Google Scholar 

  • Shimoda K, Hikasa C, Nishikawa S, Takahashi K (1987) A case report of Captopril induced parkinsonism. Clin Neurol 27: 366–368

    CAS  Google Scholar 

  • Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245: 519–522

    Article  PubMed  CAS  Google Scholar 

  • Teychenne P, Bergstrud D, Racy A, Elton RL, Vern B (1982) Bromocriptine: low dose therapy in Parkinson’s disease. Neurology 32: 577–583

    Article  PubMed  CAS  Google Scholar 

  • The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371

    Article  Google Scholar 

  • The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183

    Article  Google Scholar 

  • The Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol 39: 37–45

    Article  Google Scholar 

  • Timberlake WH, Vance MA (1978) Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa. Ann Neurol 3: 119–128

    Article  PubMed  CAS  Google Scholar 

  • van der Drift JHA (1977) Long-term clinical experience with levodopa and anticholinergics: therapeutic considerations. In: Lakke JPW et al. (eds) Parkinson’s disease. Concept and prospects. Excerpta Medica, Amsterdam Oxford, pp 111–116

    Google Scholar 

  • Verhagen Metman L, del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN (1998) Blockade of glutaminergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Amino Acids 14: 75–82

    Article  PubMed  CAS  Google Scholar 

  • Völler GW (1970) Die Behandlung des Parkinson-Syndroms mit Amantadin. Dtsch Med Wochenschr 95: 934–937

    Article  PubMed  Google Scholar 

  • Walker JE, Albers JW, Tourtelotte WW, Henderson WG, Potvin AR, Smith A (1972) A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson’s disease. J Chron Dis 25: 149–182

    Article  PubMed  CAS  Google Scholar 

  • Webster DD, Sawyer GT (1984) The combined use of amantadine HCl and levodopa/carbidopa in Parkinson’s disease. Curr Ther Res Clin Exp 35: 1010–1013

    Google Scholar 

  • Weiner WJ, Factor SA, Sanchez-Ramos JR, Singer C, Sheldon RN, Cornelius L, Ingenito A (1993) Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson’s disease. Neurology 43: 21–27

    Article  PubMed  CAS  Google Scholar 

  • Wesemann W (1984) Aspekte zum Wirkungsmechanismus von Amantadinen. In: Danielczyk W, Wesemann W (Hrsg) Amantadin-Workshop, Edition Materia Medica. Sociomedico, Gräfelfing, S 15–23

    Google Scholar 

  • Whyte RR, Hunter KR, Laurence DR, Stern GM, Armitage P (1971) Levodopa and orphen-adrine hydrochloride in parkinsonism. Eur J Clin Pharmacol 4: 18–21

    Article  PubMed  CAS  Google Scholar 

  • Wilson JA, Farquhar DL, Primrose WR, Smith RG (1987) Long term amantadine treatment. The danger of withdrawal. Scot Med J 32: 135

    PubMed  CAS  Google Scholar 

  • Yahr MD (1971) Results of long-term administration of L-Dopa. In: de Ajuriaguerra J, Gauthier G (eds) Monoamines noyoux gris centraux et syndrome de Parkinson. Georg, Geneve, pp 403–410

    Google Scholar 

  • Zeldovicz LR, Huberman J (1973) Long-term therapy of Parkinson’s disease with amantadine, alone and combined with levodopa. Can Med Assoc J 109: 588–593

    Google Scholar 

Download references

Authors
  1. E. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Bezirkskrankenhaus Gabersee, Wasserburg/Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, Österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Wien

About this chapter

Cite this chapter

Schneider, E. (1999). Kombinierte Therapien. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6400-6_33

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7315-2

  • Online ISBN: 978-3-7091-6400-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation